2026-527050-40-00Not yet recruitingPhase 1
Mass Balance and Absolute Bioavailability of [14C]-VH4011499
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Nov 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 7 Sept 2026
- Start date
- 29 Oct 2026
- Lead sponsor
- Viiv Healthcare UK Limited
- EU CT number
- 2026-527050-40-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 18
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 64 years. It studies how the body handles the drug VH4011499, a medicine for HIV infection. Healthy volunteers can join.
- Age
- 18 to 64 years
- Sex
- Men and women can join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.